QuidelOrtho Corp. Aktie
26,00 €
Deine Einschätzung
QuidelOrtho Corp. Aktie
Was spricht für und gegen QuidelOrtho Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von QuidelOrtho Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | -2,21 % | 2,36 % | -4,41 % | -10,34 % | -38,10 % | -74,90 % | -88,18 % |
Veeva Systems A | -2,86 % | -1,34 % | -6,05 % | 37,91 % | 16,19 % | 15,40 % | 5,00 % |
Thermo Fisher Scientific Inc. | 1,23 % | 1,74 % | 2,88 % | -25,51 % | -25,50 % | -33,03 % | 9,86 % |
Waters Corp. | 0,07 % | 0,95 % | -3,71 % | 11,94 % | -16,17 % | -11,58 % | 81,77 % |
Kommentare
News

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and

QuidelOrtho to Report First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and